Knight Therapeutics - President and CEO, Samira Sakhia.
President and CEO, Samira Sakhia.
Source: Knight Therapeutics.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Knight Therapeutics (GUD) affiliate United Medical has relaunched AKYNZEO in Brazil
  • AKYNZEO prevents chemotherapy-induced acute and delayed nausea and vomiting
  • The medication is also available in Canada, Argentina, Uruguay and Paraguay
  • Knight Therapeutics is a specialty pharmaceutical company focused on acquiring or licensing products for Canada and Latin America
  • Knight Therapeutics (GUD) is up by 1.12 per cent trading at $5.40 per share

Knight Therapeutics’ (GUD) affiliate United Medical has relaunched AKYNZEO in Brazil.

AKYNZEO (netupitant / palonosetron) is approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. 

In May 2022, Knight and Helsinn Healthcare SA announced an exclusive license, distribution and supply agreement for oral/IV AKYNZEO in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV (palonosetron) in Canada.

According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7M in 2021.

“We are proud to continue providing patients and physicians with leading and guideline-recommended treatments like AKYNZEO,” said Samira Sakhia, Knight’s President and CEO. “AKYNZEO is synergistic with our existing oncology portfolio and will leverage the existing commercial and medical footprint.”

Knight Therapeutics is a specialty pharmaceutical company focused on acquiring or licensing products for Canada and Latin America. 

Knight Therapeutics (GUD) is up by 1.12 per cent trading at $5.40 per share as of 10:04 am EST.

More From The Market Herald
Small Pharma - CEO, George Tziras.

" Small Pharma (TSXV:DMT) announces NCIB

Small Pharma (DMT) has received TSXV approval for a normal course issuer bid.
Spectral Medical Inc. - CMO, Dr. John Kellum

" Spectral (TSX:EDT) gets FDA approval for Tigris trial

Spectral Medical (EDT) announced that the U.S. Food and Drug Administration (FDA) has approved ten new clinical trial sites for the Tigris trial.

" Diagnos (TSXV:ADK) receives approval for its AI enabled Pathology Detection Systems

Diagnos (ADK) has received approval from the Costa Rican regulatory agency for its Artificial Intelligence (AI) enabled Pathology Detection Systems.

" BioHarvest (CSE:BHSC) launches first major U.S marketing campaign

BioHarvest Sciences (BHSC) has announced the first multimedia campaign for VINIA in the USA, Phase 1.